A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.

Wang-Gillam A, Tew WP, Rothenberg ML, Dupont J, Cooper W, Sternas L, Buzenet G, Sosman JA, Spriggs DR, Lockhart AC
Invest New Drugs. 2012 30 (5): 1958-61

PMID: 22002018 · PMCID: PMC3432791 · DOI:10.1007/s10637-011-9753-y

Targeting angiogenesis is a valid anti-cancer strategy. Aflibercept is designed to sequester circulating vascular endothelial growth factor (VEGF) by preventing VEGF from binding to its receptors. This phase I study was to evaluate a new formulation of subcutaneously administered aflibercept in patients with advanced solid tumors. Here we report our experience with the toxicity, pharmacokinetic profile and efficacy of the new 100 mg/mL subcutaneous (SC) formulation of aflibercept administered at a dose of at 4 mg/kg every 2 weeks.

MeSH Terms (15)

Adult Aged Angiogenesis Inhibitors Antineoplastic Agents Chemistry, Pharmaceutical Cohort Studies Female Humans Male Middle Aged Neoplasms Neovascularization, Pathologic Receptors, Vascular Endothelial Growth Factor Recombinant Fusion Proteins Vascular Endothelial Growth Factor A

Connections (1)

This publication is referenced by other Labnodes entities: